A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19

by Vibeke Backer, Ulf Sjöbring, Jesper Sonne, Anne Weiss, Morten Hostrup, Helle Krogh Johansen, Victoria Becker, David P. Sonne, Torben Balchen, Mads Jellingsø, Morten Otto Alexander Sommer
Published 2021-05-01